Steven Cohen’s Enanta Pharmaceuticals ENTA Stock Holding History

Steven Cohen’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-438,939	Closed	-$6.92M	–	3966
2025 Q4	$6.92M	Buy	438,939 +138,939	+46%	+$1.76M	0.01%	1584
2025 Q3	$3.59M	Buy	+300,000	New	+$2.4M	0.01%	1193
2024 Q4	–	Sell	-87,190	Closed	-$903K	–	2170
2024 Q3	$903K	Buy	+87,190	New	+$1.14M	﹤0.01%	1454
2023 Q4	–	Sell	-25,932	Closed	-$290K	–	2326
2023 Q3	$290K	Buy	25,932 +17,732	+216%	+$286K	﹤0.01%	1664
2023 Q2	$175K	Sell	8,200 -3,768	-31%	-$111K	﹤0.01%	1460
2023 Q1	$484K	Buy	+11,968	New	+$571K	﹤0.01%	1239
2022 Q3	–	Sell	-28,700	Closed	-$1.36M	–	1484
2022 Q2	$1.36M	Buy	+28,700	New	+$1.56M	0.01%	1017
2019 Q3	–	Sell	-400	Closed	-$34K	–	1208
2019 Q2	$34K	Buy	+400	New	+$36K	﹤0.01%	1209
2018 Q4	–	Sell	-8,400	Closed	-$718K	–	1028
2018 Q3	$718K	Buy	+8,400	New	+$841K	﹤0.01%	892
2017 Q2	–	Sell	-56,200	Closed	-$1.73M	–	873
2017 Q1	$1.73M	Buy	+56,200	New	+$1.75M	0.01%	683

Other funds holding ENTA

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SSC

Spruce Street Capital New York $510M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Steven Cohen's ENTA Position: Q1 2026 in Review

Steven Cohen sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 438,939 shares — an estimated $6.92M sold.

Steven Cohen first reported a position in ENTA in Q1 2017 and held it in 10 quarters. The position peaked at $6.92M in Q4 2025. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Steven Cohen reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 438,939 Enanta Pharmaceuticals shares in Q1 2026, an estimated $6.92M.
Steven Cohen first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 10 quarters.
Steven Cohen's Enanta Pharmaceuticals position peaked at $6.92M in Q4 2025.
133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.